Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | RXRG | P48443 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2531690 | 0.98 | PTGS1 (0.58) | PTGS1AKR1C3AKR1C2LMNAKDM4E | |
| SCHEMBL5742710 | 0.88 | AKR1C2 (0.57) | PTGS1AKR1C3AKR1C2LMNAKDM4E | |
| SCHEMBL5315605 | 0.88 | CALM1 (0.54) | PTGS1AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL31337559 | 0.88 | AKR1C2 (0.57) | PTGS1AKR1C3AKR1C2LMNAKDM4E | |
| SCHEMBL17414533 | 0.88 | PTGS1 (0.53) | PTGS1AKR1C3AKR1C2LMNAKDM4E | |
| SCHEMBL14856202 | 0.87 | PTGS1 (0.51) | PTGS1AKR1C3AKR1C2LMNAKDM4E | |
| SCHEMBL31337475 | 0.87 | PTGS1 (0.51) | PTGS1AKR1C3AKR1C2LMNAKDM4E | |
| SCHEMBL6367068 | 0.87 | PTGS1 (0.51) | PTGS1AKR1C3AKR1C2KDM4EPOLB | |
| SCHEMBL10350883 | 0.87 | PTGS1 (0.51) | PTGS1AKR1C3AKR1C2LMNAKDM4E | |
| SCHEMBL15728088 | 0.86 | RXRA (0.51) | PTGS1AKR1C3AKR1C2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 808 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119770481-B | NR4A1 transcriptional activity inhibitor and application thereof | 浙江省肿瘤医院 | 2025-06-13 | — | — | CN | claimed |
| CN-119770481-A | NR4A1 transcriptional activity inhibitor and application thereof | 浙江省肿瘤医院 | 2025-04-08 | — | — | CN | claimed |
| US-20240309000-A1 | Process for Preparing an FGFR Inhibitor | PRINCIPIA BIOPHARMA, INC. (US) | 2024-09-19 | — | — | US | claimed |
| CN-114605260-B | Synthesis method of fungal polyketone Cytosporone B | 山东大学 | 2023-04-14 | — | — | CN | claimed |
| CN-114605260-A | Synthesis method of fungal polyketone Cytosporone B | 山东大学 | 2022-06-10 | — | — | CN | claimed |
| CN-114539100-A | Terbutaline derivative D and preparation method and application thereof | 嘉实（湖南）医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-103664537-B | Preparation method for resveratrol | HUNAN KEYUAN BIO PRODUCTS CO LTD | 2015-06-24 | — | — | CN | claimed |
| CN-103373974-B | Preparation method of 2-(4-hydroxyphenyl)-5,7-dimethoxy benzofuran | CAS GUANGZHOU CHEMISTRY CO LTD | 2015-02-04 | — | — | CN | claimed |
| CN-103664537-A | Preparation method for resveratrol | HUNAN KEYUAN BIO PRODUCTS CO LTD | 2014-03-26 | — | — | CN | claimed |
| CN-103373974-A | Preparation method of 2-(4-hydroxyphenyl)-5,7-dimethoxy benzofuran | CAS GUANGZHOU CHEMISTRY CO LTD | 2013-10-30 | — | — | CN | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| CN-1686999-A | 1-carboxy-1-(3,5-dimethoxy phenyl)-2-(4-R group phenyl) ethano and preparation method thereof | JIANGSU PROV ATOMIC MEDICINE I (CN) | 2005-10-26 | — | — | CN | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-6398857-B1 | ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS | XEROX CORPORATION | 2002-06-04 | — | — | US | claimed |
| WO-1995011895-A1 | N-BENZOYL-4-OXY/THIO-2-SUBSTITUTED PIPERIDINES AS SUBSTANCE-P RECEPTOR ANTAGONISTS | CIBA-GEIGY AG (CH) | 1995-05-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240309000-A1 | Process for Preparing an FGFR Inhibitor | FGFR1, FGFR2, FGFR3 | PTGS1 2761/4885AKR1C3 3751/4885AKR1C2 3066/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | PTGS1 4504/4885AKR1C3 1660/4885AKR1C2 2523/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | PTGS1 3413/4885AKR1C3 3104/4885AKR1C2 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.